Associate, Center for Toxicology, Director, Pharmacogenomics, Endowed Professor, Holslaw - Pharmacogenomics, Professor, Applied BioSciences - GIDP, Professor, BIO5 Institute, Professor, Cancer Biology - GIDP, Professor, Genetics - GIDP, Professor, Pharmacogenomics, Professor, Pharmacology, Professor, Pharmacology and Toxicology
Professor, BIO5 Institute, Professor, Neuroscience - GIDP, Professor, Pharmacology, Professor, Pharmacology and Toxicology, Professor, Physiological Sciences - GIDP
Assistant Professor, Neuroscience - GIDP, Assistant Professor, Pharmacology
Dr. Khanna has worked in the areas of RNA, RNA-protein, and protein-protein interactions for over 10 years. Dr. Khanna's has a background in chemistry, structural biology, biophysics and drug discovery in neurodegenerative diseases. In her laboratory, she hsa several exciting ongoing projects that all focus on drug discovery using small molecules, peptides and aptamers. The Khanna laboratory develops inhibitors for difficult to target RNA-protein and protein-protein interfaces.
Professor, Anesthesiology, Professor, BIO5 Institute, Professor, Neuroscience - GIDP, Professor, Pharmacology
The focus of my laboratory’s’ research is to understand how ion channels, specifically, voltage-gated calcium and sodium channels, are regulated by novel protein interactions. Recent studies in my laboratory have focused on targeting protein-protein interactions with biologics (peptide aptamers) and small molecules; testing the activity of these novel chemical entities in biochemical and immunofluorescent-based assays of trafficking; examining their protein interaction signatures; testing them with whole cell voltage-clamp electrophysiology and voltage- and calcium sensitive fluorescence-based imaging. Regulating these protein networks to modulate the activity of ion channels in neurodegenerative diseases (Chronic Pain, Migraine, and Neurofibromatosis) is a key focus of the laboratory.